- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.80 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 15 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.2: 10 residues within 4Å:- Chain C: S.95
- Chain D: N.271, I.292
- Chain F: V.54, V.55, G.56, I.57, Y.58, K.59, Y.113
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.26: 10 residues within 4Å:- Chain I: S.95
- Chain J: N.271, I.292
- Chain L: V.54, V.55, G.56, I.57, Y.58, K.59, Y.113
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.50: 10 residues within 4Å:- Chain O: S.95
- Chain P: N.271, I.292
- Chain R: V.54, V.55, G.56, I.57, Y.58, K.59, Y.113
No protein-ligand interaction detected (PLIP)- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.3: 4 residues within 4Å:- Chain D: T.105, N.107, D.110
- Ligands: NAG.17
No protein-ligand interaction detected (PLIP)NAG-NAG.4: 4 residues within 4Å:- Chain D: N.204, T.206, H.321
- Ligands: NAG.19
No protein-ligand interaction detected (PLIP)NAG-NAG.10: 6 residues within 4Å:- Chain D: Q.263, N.265, N.301, V.302, S.303, R.412
No protein-ligand interaction detected (PLIP)NAG-NAG.27: 4 residues within 4Å:- Chain J: T.105, N.107, D.110
- Ligands: NAG.41
No protein-ligand interaction detected (PLIP)NAG-NAG.28: 4 residues within 4Å:- Chain J: N.204, T.206, H.321
- Ligands: NAG.43
No protein-ligand interaction detected (PLIP)NAG-NAG.34: 6 residues within 4Å:- Chain J: Q.263, N.265, N.301, V.302, S.303, R.412
No protein-ligand interaction detected (PLIP)NAG-NAG.51: 4 residues within 4Å:- Chain P: T.105, N.107, D.110
- Ligands: NAG.65
No protein-ligand interaction detected (PLIP)NAG-NAG.52: 4 residues within 4Å:- Chain P: N.204, T.206, H.321
- Ligands: NAG.67
No protein-ligand interaction detected (PLIP)NAG-NAG.58: 6 residues within 4Å:- Chain P: Q.263, N.265, N.301, V.302, S.303, R.412
No protein-ligand interaction detected (PLIP)- 6 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.6: 3 residues within 4Å:- Chain D: T.105, N.118, Y.135
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.8: 6 residues within 4Å:- Chain D: N.332, S.333, S.334, S.357
- Ligands: NAG-NAG-BMA.15, NAG-NAG-BMA.15
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.30: 3 residues within 4Å:- Chain J: T.105, N.118, Y.135
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.32: 6 residues within 4Å:- Chain J: N.332, S.333, S.334, S.357
- Ligands: NAG-NAG-BMA.39, NAG-NAG-BMA.39
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.54: 3 residues within 4Å:- Chain P: T.105, N.118, Y.135
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.56: 6 residues within 4Å:- Chain P: N.332, S.333, S.334, S.357
- Ligands: NAG-NAG-BMA.63, NAG-NAG-BMA.63
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN-MAN.7: 19 residues within 4Å:- Chain C: S.32, W.33, A.51, A.57, Y.92
- Chain D: T.267, H.299, N.301, R.412
- Chain F: W.99, R.100, C.102, C.105, Y.107, D.108, Y.112, N.114, D.115, D.118
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:Y.107
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN-MAN.31: 19 residues within 4Å:- Chain I: S.32, W.33, A.51, A.57, Y.92
- Chain J: T.267, H.299, N.301, R.412
- Chain L: W.99, R.100, C.102, C.105, Y.107, D.108, Y.112, N.114, D.115, D.118
1 PLIP interactions:1 interactions with chain L- Hydrogen bonds: L:Y.107
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN-MAN.55: 19 residues within 4Å:- Chain O: S.32, W.33, A.51, A.57, Y.92
- Chain P: T.267, H.299, N.301, R.412
- Chain R: W.99, R.100, C.102, C.105, Y.107, D.108, Y.112, N.114, D.115, D.118
1 PLIP interactions:1 interactions with chain R- Hydrogen bonds: R:Y.107
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.9: 5 residues within 4Å:- Chain D: S.357, G.358, N.361
- Ligands: NAG-NAG-BMA.15, NAG-NAG-BMA.15
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN.33: 5 residues within 4Å:- Chain J: S.357, G.358, N.361
- Ligands: NAG-NAG-BMA.39, NAG-NAG-BMA.39
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN.57: 5 residues within 4Å:- Chain P: S.357, G.358, N.361
- Ligands: NAG-NAG-BMA.63, NAG-NAG-BMA.63
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN.13: 19 residues within 4Å:- Chain A: N.30, F.31, Y.32, H.33, S.52, Y.54, S.55, D.57, N.59, L.109, R.110, D.111, G.112, S.113, T.115
- Chain B: H.95, N.96
- Chain D: N.58
- Chain E: S.17
4 PLIP interactions:3 interactions with chain A, 1 interactions with chain B- Hydrogen bonds: A:T.115, B:H.95, A:H.33, A:S.52, A:S.52
NAG-NAG-BMA-MAN-MAN-MAN-MAN.37: 19 residues within 4Å:- Chain G: N.30, F.31, Y.32, H.33, S.52, Y.54, S.55, D.57, N.59, L.109, R.110, D.111, G.112, S.113, T.115
- Chain H: H.95, N.96
- Chain J: N.58
- Chain K: S.17
4 PLIP interactions:1 interactions with chain H, 3 interactions with chain G- Hydrogen bonds: H:H.95, G:T.115, G:H.33, G:S.52, G:S.52
NAG-NAG-BMA-MAN-MAN-MAN-MAN.61: 19 residues within 4Å:- Chain M: N.30, F.31, Y.32, H.33, S.52, Y.54, S.55, D.57, N.59, L.109, R.110, D.111, G.112, S.113, T.115
- Chain N: H.95, N.96
- Chain P: N.58
- Chain Q: S.17
4 PLIP interactions:1 interactions with chain N, 3 interactions with chain M- Hydrogen bonds: N:H.95, M:T.115, M:H.33, M:S.52, M:S.52
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.14: 9 residues within 4Å:- Chain D: K.35, E.181, L.231, N.232, N.346, G.348, V.414, S.415
- Ligands: NAG.18
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:G.348
NAG-NAG-BMA-MAN-MAN.38: 9 residues within 4Å:- Chain J: K.35, E.181, L.231, N.232, N.346, G.348, V.414, S.415
- Ligands: NAG.42
1 PLIP interactions:1 interactions with chain J- Hydrogen bonds: J:G.348
NAG-NAG-BMA-MAN-MAN.62: 9 residues within 4Å:- Chain P: K.35, E.181, L.231, N.232, N.346, G.348, V.414, S.415
- Ligands: NAG.66
1 PLIP interactions:1 interactions with chain P- Hydrogen bonds: P:G.348
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.16: 6 residues within 4Å:- Chain B: R.56, G.59, I.60
- Chain E: N.92, R.93, N.94
No protein-ligand interaction detected (PLIP)NAG-NAG.40: 6 residues within 4Å:- Chain H: R.56, G.59, I.60
- Chain K: N.92, R.93, N.94
No protein-ligand interaction detected (PLIP)NAG-NAG.64: 6 residues within 4Å:- Chain N: R.56, G.59, I.60
- Chain Q: N.92, R.93, N.94
No protein-ligand interaction detected (PLIP)- 24 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.17: 8 residues within 4Å:- Chain D: N.103, N.107, D.110, G.114, E.115, K.117, Y.161
- Ligands: NAG-NAG.3
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain D: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.14
Ligand excluded by PLIPNAG.19: 4 residues within 4Å:- Chain D: N.246, N.249
- Ligands: NAG-NAG.4, NAG-NAG.4
Ligand excluded by PLIPNAG.20: 4 residues within 4Å:- Chain D: R.319, N.324, N.325, S.366
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain D: I.365, S.366, N.367
Ligand excluded by PLIPNAG.22: 9 residues within 4Å:- Chain A: Y.32, K.106, G.107, L.108, Y.119
- Chain E: R.93, E.97, N.101, Q.106
Ligand excluded by PLIPNAG.23: 1 residues within 4Å:- Chain E: N.113
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain E: N.87, S.89
Ligand excluded by PLIPNAG.41: 8 residues within 4Å:- Chain J: N.103, N.107, D.110, G.114, E.115, K.117, Y.161
- Ligands: NAG-NAG.27
Ligand excluded by PLIPNAG.42: 4 residues within 4Å:- Chain J: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.38
Ligand excluded by PLIPNAG.43: 4 residues within 4Å:- Chain J: N.246, N.249
- Ligands: NAG-NAG.28, NAG-NAG.28
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain J: R.319, N.324, N.325, S.366
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain J: I.365, S.366, N.367
Ligand excluded by PLIPNAG.46: 9 residues within 4Å:- Chain G: Y.32, K.106, G.107, L.108, Y.119
- Chain K: R.93, E.97, N.101, Q.106
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain K: N.113
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain K: N.87, S.89
Ligand excluded by PLIPNAG.65: 8 residues within 4Å:- Chain P: N.103, N.107, D.110, G.114, E.115, K.117, Y.161
- Ligands: NAG-NAG.51
Ligand excluded by PLIPNAG.66: 4 residues within 4Å:- Chain P: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.62
Ligand excluded by PLIPNAG.67: 4 residues within 4Å:- Chain P: N.246, N.249
- Ligands: NAG-NAG.52, NAG-NAG.52
Ligand excluded by PLIPNAG.68: 4 residues within 4Å:- Chain P: R.319, N.324, N.325, S.366
Ligand excluded by PLIPNAG.69: 3 residues within 4Å:- Chain P: I.365, S.366, N.367
Ligand excluded by PLIPNAG.70: 9 residues within 4Å:- Chain M: Y.32, K.106, G.107, L.108, Y.119
- Chain Q: R.93, E.97, N.101, Q.106
Ligand excluded by PLIPNAG.71: 1 residues within 4Å:- Chain Q: N.113
Ligand excluded by PLIPNAG.72: 2 residues within 4Å:- Chain Q: N.87, S.89
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kumar, S. et al., A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Sci Adv (2020)
- Release Date
- 2020-09-23
- Peptides
- 35O22 Fab Heavy Chain: AGM
35O22 Fab Light Chain: BHN
B11 Fab Light Chain: CIO
Envelope glycoprotein gp120: DJP
Envelope glycoprotein gp41: EKQ
B11 Fab Heavy chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
DG
DM
DB
EH
EN
EC
LI
LO
LD
GJ
GP
GE
TK
TQ
TF
HL
HR
H
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.80 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 15 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 24 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kumar, S. et al., A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Sci Adv (2020)
- Release Date
- 2020-09-23
- Peptides
- 35O22 Fab Heavy Chain: AGM
35O22 Fab Light Chain: BHN
B11 Fab Light Chain: CIO
Envelope glycoprotein gp120: DJP
Envelope glycoprotein gp41: EKQ
B11 Fab Heavy chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
DG
DM
DB
EH
EN
EC
LI
LO
LD
GJ
GP
GE
TK
TQ
TF
HL
HR
H